Skip to main content
Figure 3 | Orphanet Journal of Rare Diseases

Figure 3

From: VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Figure 3

BAY 55-9837 upregulates SMN protein in SMA mouse model. SMA∆7 mice were treated daily with saline or BAY 55-9837 (200 μg/kg) from P1 for 6 days, then sacrificed at P7. Brain, spinal cord,skeletal muscle and heart tissues were harvested for western blot analysis. Representative western blots showing effect of BAY 55-9837 on SMN protein in brain (a), spinal cord (c), muscle (e) and heart (g) samples of SMA∆7 mice treated with Saline (control, lane 1, 2 & 3) or BAY 55-9837 (treatment lane 1, 2 & 3 respectively) (each lane represents individual animal; all lanes were run on the same gel but were non-contiguous). Densitometric quantification of SMN relative to Actin/Tubulin [mean + SEM (bars)] is shown for brain (b; n=11), spinal cord (d; n=6), muscle (f; n=11) and heart (h; n=11) samples. *P < 0.05; **P < 0.01; t-test.

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172